Danish Cancer Biobank

Danish Cancer Biobank
Name	Danish Cancer Biobank
Formation	2009
Type	Biobank
Headquarters	Copenhagen
Location	Copenhagen University Hospital, Denmark
Region served	Denmark

Danish Cancer Biobank

The Danish Cancer Biobank is a national repository for human biospecimens established to support cancer research, translational studies, and clinical trials across Denmark. It connects regional university hospitals, academic centres such as University of Copenhagen, and national research infrastructures including European Molecular Biology Laboratory-affiliated initiatives to provide characterized tissue, blood, and DNA/RNA resources for investigators. The biobank integrates with registries and platforms like Danish Cancer Registry, Nordic Genomics, and collaborative projects involving institutions such as Rigshospitalet, Aarhus University Hospital, and Technical University of Denmark.

Overview

The biobank functions as a centralized resource linking sample accrual from clinical sites like Odense University Hospital, Aalborg University Hospital, and Herlev Hospital with research units at University of Southern Denmark, Copenhagen University Hospital Herlev, and specialty centres including Danish Centre for Translational Research in Oncology. It catalogs biospecimens using standards aligned with international bodies such as International Society for Biological and Environmental Repositories, European Biobanking and BioMolecular resources Research Infrastructure, and initiatives associated with Horizon 2020, facilitating interoperable datasets for projects with partners like Wellcome Trust, European Commission, and multinational consortia involving Max Planck Society and Karolinska Institutet.

History and Development

The programme was initiated in the late 2000s as part of national efforts involving stakeholders from Danish Council for Independent Research, regional health authorities in Capital Region of Denmark, and academic leaders from University of Copenhagen and Aarhus University. Development phases paralleled landmark projects such as The Cancer Genome Atlas collaborations and drew on biobanking models established by UK Biobank and FinnGen. Key milestones included establishment of standard operating procedures influenced by International Organization for Standardization frameworks, expansion of collection sites across Region Zealand, and integration with registries like Danish National Patient Registry to enable longitudinal linkage.

Governance and Funding

Governance structures involve oversight from hospital administrations at facilities such as Rigshospitalet and academic committees from University of Copenhagen and Aarhus University. Funding sources have included grants from national bodies such as Danish Cancer Society, project funding from Innovation Fund Denmark, and participation in EU programmes administered by European Research Council and Horizon Europe. Collaborative agreements have been made with pharmaceutical partners including Novo Nordisk, multinational corporations active in oncology, and philanthropic institutions similar to Lundbeck Foundation and Carlsberg Foundation.

Sample Collection and Processing

Specimen types collected include formalin-fixed paraffin-embedded tissue, fresh-frozen tumour samples, peripheral blood mononuclear cells, plasma, serum, and extracted nucleic acids, obtained under protocols coordinated with pathology departments at Rigshospitalet and biochemistry units at Herlev Hospital. Processing pipelines use automated platforms analogous to those deployed at Broad Institute and quality-control benchmarks referenced to standards from World Health Organization laboratories and technical committees like Clinical and Laboratory Standards Institute. Integration with digital pathology systems and molecular assays aligns with capabilities at centres such as Dana–Farber Cancer Institute and genomic sequencing collaborations with facilities like European Molecular Biology Laboratory.

Research and Collaboration

The repository supports studies spanning molecular oncology, biomarker discovery, and personalised medicine involving collaborators from Karolinska Institutet, University College London, McGill University, and biotech partners similar to Genmab. It has enabled translational projects linked to clinical trial networks including those organized by European Organisation for Research and Treatment of Cancer and multicentre studies with participants drawn from hospital networks in Region of Southern Denmark and Capital Region of Denmark. Cross-disciplinary collaborations connect clinicians from Rigshospitalet with bioinformaticians at Technical University of Denmark and epidemiologists affiliated with Statens Serum Institut.

Ethical, Legal, and Privacy Considerations

Ethical oversight is provided through regional ethics committees such as Danish National Committee on Health Research Ethics and institutional review boards at University of Copenhagen and Aarhus University. Consent frameworks reference international guidance from bodies like Council of Europe and privacy standards resonant with regulations including General Data Protection Regulation while coordinating with national laws administered by agencies such as Danish Data Protection Agency. Procedures for de-identification, controlled access, and data linkage follow precedents set by large-scale projects like UK Biobank and ethics deliberations seen in cases considered by European Court of Human Rights.

Impact and Notable Studies

Samples from the biobank have supported genomic profiling, biomarker validation, and population-based oncology studies cited in collaborations with groups at Karolinska Institutet, Memorial Sloan Kettering Cancer Center, Harvard Medical School, and Imperial College London. Research outputs have contributed to understanding molecular subtypes of common cancers, informing therapeutic strategies evaluated in trials coordinated with European Society for Medical Oncology and influencing health policy discussions within Danish institutions like Danish Health Authority. Notable research themes include tumor heterogeneity analyses akin to studies at Broad Institute, biomarker panels comparable to efforts at MD Anderson Cancer Center, and translational projects leading to patents and partnerships with companies similar to Novartis and Roche.

Category:Biobanks Category:Cancer research in Denmark